Tardive dyskinesia is a complication associated with long term neuroleptic drug treatment that can be the object of litigation. Such litigation has occurred recently in the United States, where awards of considerable value have been granted to plaintiffs. Circumstances that can lead to TD litigation are presented as well as guidelines for the prescription of neuroleptics, the prevention of litigation and of the syndrome itself. Five lawsuits associated with TD serve as a backdrop for the discussion.
References
1.
ShriquiC.L.Dyskinésie tardive: mise à jour.Revue canadienne de psychiatrie1988; 33(7): 637–644.
2.
Tardive dyskinesia: report of the American Psychiatric Association Task Force on late neurological effects of antipsychotic drugs. APA Task Force Report 18.Washington DC: American Psychiatric Press Inc., 1979.
3.
CaseyD.E.Tardive dyskinesia. In: MeltzerH.Y., ed. Psychopharmacology: the third generation of progress.New York: Raven Press,1987: 1411–1419.
4.
CaseyD.E.Tardive dyskinesia: epidemiologic factors as guide for prevention and management.Adv Biochem Psychopharmacol1985; 40: 15–22.
5.
KaneJ.M., SmithJ.M.Tardive dyskinesia prevalence and risk factors: 1959 to 1979.Arch Gen Psychiatry1982; 39: 473–481.
CaseyD.E., GerlachJ.Tardive dyskinesia: what is the long-term outcome? In: CaseyD.E., GardosG., eds. Tardive dyskinesia and neuroleptics: from dogma to reason.Washington DC: American Psychiatric Press, Inc.,1986: 75–97.
38.
ChouinardG., AnnableL., Ross-ChouinardA.A 5-year prospective longitudinal study of tardive dyskinesia: factors predicting appearance of new cases.J Clin Psychopharmacol1988 (Suppl); 8(4): 21–26.
39.
ChouinardG., AnnableL., Ross-ChouinardA.A ten-year follow-up study of tardive dyskinesia. Paper presented at the 39th Annual Meeting of the Canadian Psychiatric Association, St. John's, Newfoundland, September 1989.
40.
KaneJ., LiebermanJ., WoernerM.Tardive dyskinesia: new research. In: SchulzS.C., TammingaC.A., eds. Scizophrenia: scientific progress.Oxford University Press, 1989: 381–386.
41.
WolfM.A., WertenschlagN.Facteurs de risque et prévention des dyskinésies tardives.Revue canadienne de psychiatrie1989; 34(3): 177–181.
42.
GuyW.ECDEU assessment manual for psychopharmacology.Washington DC: US Department of Health, Education and Welfare,1976.
TammingaC.A., ThakerG.K.Tardive dyskinesia.Current Opinion in Psychiatry1989; 2: 12–16.
45.
RemingtonG.Pharmacotherapy of schizophrenia.Can J Psychiatry1989; 34(3): 211–220.
46.
JesteD.V., LohrJ.B., ClarkK.Pharmacological treatments of tardive dyskinesia in the 1980s.J Clin Psychopharmacol1988; 8: 38S–48S.
47.
LohrJ.B., CadetJ.L., LohrM.A.Vitamin E in the treatment of tardive dyskinesia: the possible involvement of free radical mechanisms.Schizophr Bull1988; 14(2): 291–296.
ShriquiC., JonesB.Free radical involvement in schizophrenia and tardive dyskinesia.Schizophrenia Research1990; 3(1): 81.
50.
SnyderS.H., LargentB.L.Receptor mechanisms in antipsychotic drug action: focus on sigma receptors.Journal of Neuropsychiatry and Clinical Neurosciences1989; 1(1): 7–15.
51.
LamR.W., JesteS.D., JesteD.V.Preventing neuroleptic induced tardive dyskinesia in adults and children.Encephale1988; 14: 251–255.
52.
JesteD.V., WyattR.J.Prevention and management of tardive dyskinesia.J Clin Psychiatry1985; 46(4): 14–18.
53.
KlawansH.L.Recognition and diagnosis of tardive dyskinesia.J Clin Psychiatry1985; 46(4): 3–7.
54.
SharmaR.Atypical antipsychotics.Current Opinion in Psychiatry1989; 2: 49–53.
55.
MeltzerH.Y.Clozapine: clinical advantages and biologic mechanisms. In: SchulzS.C., TammingaC.A., eds. Schizophrenia: scientific progress.Oxford University Press, 1989: 302–307.
56.
TammingaC.A., GerlachJ.New neuroleptics and experimental antipsychotics in schizophrenia. In: MeltzerH.Y., ed. Psychopharmacology: the third generation of progress.New York: Raven Press,1987: 1129–1140.
